The Indian pharmaceutical industry sees US President-elect Joe Biden’s proposed plan to expand Obamacare and reduce middlemen as positive steps. Looking to benefit from the Biden presidency on the back of an increased push for generic prescriptions and biosimilar strategy, Indian drugmakers expect the accent on localization to continue, reports The Pharma Letter’s India correspondent.
Generic companies in India like Dr Reddy’s, Lupin, Cipla and Aurobindo are set to benefit under ‘Bidencare’, say analysts, as are companies with biosimilars.
"Joe Biden has a plan to strengthen the Affordable Care Act (ACA) and offers more power to states to discover drug pricing. A democratic senate could clear the way for prescription drug price and healthcare coverage reforms that could impact specialty drug (high-priced as compared to generic drugs) companies like Pfizer, Sanofi, Eli Lilly, etc," said Axis Securities CIO Naveen Kulkarni.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze